Abstract: OBJECTIVE To screen the effect of dicaffeoylquinic acid compounds(DCQAs) from Artemisia ordosica for resistance to degranulation of mast cells and to explore the mechanism of the active compounds on allergic rhinitis by network pharmacology. METHODS The optimal protocols of degranulation in P815 induced by C48/80 was established by detecting cell viability, β-hexosaminidase release rate and the neutral red staining. The active DCQAs was screened by measuring the release rate of β-hexosaminidase. The target of the active DCQAs and the therapeutic targets for allergic rhinitis and mast cell degranulation were searched and collected from the database of STITCH, Swiss, TCMID, TCMSP, and GeneCards. Then the common effective targets were obtained. The network map of active DCQAs and the potential effective targets was conducted by the database of String and Cytoscape 3.7.2 software. GO(Gene Ontology) and KEGG(Kyoto Encyclopedia of Genes and Genomes) enrichment analysis were performed by DAVID database. RESULTS 3,5-DCQA and 4,5-DCQA could significantly reduce the release rate of β-hexosaminidase among the 6 kinds of DCQAs. Eighteen potential effective targets were collected and integrin β-1(ITGB1), neutrophil elastase(ELANE), 72 kDa type IV collagenase(MMP2), proto-oncogene tyrosine-protein kinase Src(SRC), and caspase-3 could be the hub proteins. GO and KEGG analysis showed that active DCQAs participated in the biological processes of MAPK positive regulation, extracellular matrix decomposition and integrin-mediated signaling pathways through leukocyte transendothelial metastasis signaling pathway GnRH signaling pathway, and tumor signaling pathway. CONCLUSION 3,5-DCQA and 4,5-DCQA are identified as potential active compounds of Artemisia ordosica extracts against allergic rhinitis, which exerted anti-allergic rhinitis effects through multiple targets-multiple pathways. It provids a scientific basis for the treatment of allergic rhinitis with Artemisia ordosica extracts.